BROOMALL, Pa., May 3, 2016 /PRNewswire/ -- ACME Markets, Delaware County District Attorney Jack Whelan and Delaware County Councilman Dave White announced today the availability of NARCAN® (naloxone HCI) Nasal Spray in all ACME pharmacies across Delaware County. According to the U.S. Centers for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives nationwide over the past 20 years. Since November 2014, when police officers in Delaware County were authorized to administer naloxone to overdose victims, 244 lives have been saved.
"In Delaware County, heroin and opioid abuse is a serious health and public safety threat that is endangering lives and tearing families apart," said Delaware County District Attorney Jack Whelan. "We believe making Narcan Nasal Spray available to first responders and police as well as families will continue to save lives and provide a chance for those suffering from addiction to get help."
Now each ACME Pharmacy in Delaware County, a total of 10 locations, will carry a carton of NARCAN® Nasal Spray on site.
"The opioid and heroin epidemic cannot be ignored," explained Danielle D'Elia, communications manager for ACME. "By stocking NARCAN® Nasal Spray in our pharmacies, we hope to give our communities – the family, friends, loved ones and caregivers of those struggling with addiction – a tool that might help prevent the avoidable loss of a loved one."
The CDC now estimates that 89 people die every day from an opioid-related overdose in the U.S., and Pennsylvania is among the highest incidence areas for opioid-related abuse and overdose.
"We want to empower our residents with lifesaving tools to help fight the battle that is going on across the country and in our own backyards," said Delaware County Councilman Dave White "Our partnership with ACME is part of our larger efforts to help our community protect itself from losing another life. From schools, to police officers, to family members- The Delaware County Heroin Task Force is working to identify ways for medications like NARCAN® Nasal Spray to be available to anyone at any time.
In October 2015, the state of Pennsylvania issued a standing order, which provides the entire state with prescription access to naloxone products at participating pharmacy locations. Co-pay costs will vary based on Medicaid and insurance plans.
"ACME is the first retail chain to make the choice to consistently stock a naloxone product in all of their pharmacies," said Thom Duddy, Executive Director, Adapt Pharma. "Their partnership with Delaware County to roll out locally first is a milestone in improving access to ready-to-use naloxone products, like NARCAN® Nasal Spray, across our communities."
NARCAN® Nasal Spray is the first and only FDA-approved naloxone nasal spray for the emergency treatment of opioid-, fentanyl- and heroin-related overdose. It is now available as a ready-to-use, needle-free, 4 mg concentrated dose of naloxone in a single spray. As the first and only FDA-approved naloxone nasal spray, NARCAN® Nasal Spray provides a ready-to-use alternative to currently available opioid overdose emergency treatments. NARCAN® Nasal Spray is not a substitute for emergency medical care. Please see Indications and Important Safety Information below.
ACME Markets Inc. began in 1891 when two friends, Samuel Robinson and Robert Crawford, opened a small neighborhood grocery store in South Philadelphia, emphasizing quality products, low prices, and friendly service. 125 years later, ACME remains dedicated to providing a high-quality grocery experience that our customers have come to expect. Today, ACME operates 178 stores, including Sav-On Pharmacies at select locations, in Pennsylvania, New Jersey, New York, Connecticut, Delaware, and Maryland, employing nearly 20,000 associates. The company and its associates remain committed to the communities they serve. For more information, visit www.acmemarkets.com.
ABOUT The Delaware County Heroin Task Force :
The mission of the Heroin Task Force is to provide young people, parents and educators with information regarding the destructive and addictive nature of heroin and abused prescription drugs. Members include Delaware County District Attorney Jack Whelan and Delaware County Councilman Dave White
Task force goals include:
- Reduce the demand for heroin and illegally used prescription drugs;
- Educate citizens about the resources available to prevent and treat addiction;
- Reduce drug-related crime in the community through public education and law enforcement.
ABOUT NARCAN® (naloxone HCl) NASAL SPRAY
NARCAN® Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
NARCAN® Nasal Spray is not a substitute for emergency medical care. Always seek emergency medical assistance in the event of a suspected, potentially life-threatening opioid emergency after administration of the first dose of NARCAN® nasal spray.
If the desired response is not obtained after 2 or 3 minutes, administer an additional dose of NARCAN® Nasal Spray using a new NARCAN® Nasal Spray. If the patient responds to NARCAN® Nasal Spray and relapses back into respiratory depression before emergency assistance arrives, administer an additional dose and continue surveillance of the patient. If there is still no response and additional doses are available, administer additional doses of NARCAN® Nasal Spray every 2 to 3 minutes using a new NARCAN® Nasal Spray with each dose until emergency medical assistance arrives. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
Please see Indications and Important Safety Information below.
Please see full prescribing information for NARCAN® Nasal Spray, available at http://www.NARCANnasalspray.com/pdf/NARCAN-Prescribing-Information.pdf
AVAILABILITY OF NARCAN® NASAL SPRAY
NARCAN® Nasal Spray was made available in February of 2016.
Qualifying group purchasers may source NARCAN® Nasal Spray directly from wholesalers and distributors. To place a pre-order immediately or for assistance in sourcing NARCAN® Nasal Spray please contact Adapt Pharma's dedicated Customer Service Team at 844-4-NARCAN® (844-462-7226) or email firstname.lastname@example.org.
NARCAN® NASAL SPRAY INDICATIONS AND IMPORTANT SAFETY INFORMATION
NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
NARCAN® Nasal Spray is not a substitute for emergency medical care.
Important Safety Information
NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.
Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.
Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.
Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.
See Instructions for Use and full prescribing information in the use of this product, available here: http://www.narcannasalspray.com/pdf/NARCAN-Prescribing-Information.pdf.
Additional information, including full prescribing information for NARCAN® Nasal Spray, and important safety information and instructions for use, is also available at www.NARCAN®NasalSpray.com.
To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN® (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
ABOUT ADAPT PHARMA
Adapt Pharma is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma's company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.
MEDIA CONTACT INFORMATION
Public Relations Officer for Delaware County Council
Executive Director, Communications & Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delaware-county-and-acme-work-together-to-improve-community-access-to-naloxone-300261854.html
SOURCE Adapt Pharma; ACME Markets; Delaware County Council